Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Noven Pharmaceuticals has registered a patent infringement lawsuit against Watson Pharmaceuticals in the US District Court of New Jersey for infringement of certain patents of Noven.
Subscribe to our email newsletter
The lawsuit was registered for submission of an abbreviated new drug application (ANDA) to the
US Food and Drug Administration’s (FDA) prior to the expiration of Noven’s patents in 2018 for approval of a generic version of its Daytrana (methylphenidate transdermal system).
Noven is engaged in the research and development of prescription pharmaceutical products.
Noven mainly focuses on three areas including transdermal drug delivery and related manufacturing, the Novogyne joint venture, and Noven Therapeutics, Noven’s specialty pharmaceutical unit.